The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world evaluation of a “hyperselection” predictive biomarker for anti-EGFR therapy benefit in patients with RAS/RAF wild-type, MMRp/MSS mCRC.
 
Nishwant Swami
No Relationships to Disclose
 
Wei-Ting Hwang
Employment - Johnson & Johnson innovative medicine (I)
Stock and Other Ownership Interests - Johnson & Johnson innovative medicine (I)
Research Funding - Novartis
 
Mark O'Hara
Consulting or Advisory Role - Alligator Bioscience; Geneos; Merus; Natera; PsiOxus Therapeutics; Strike Bio
Research Funding - Arcus Biosciences (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Geistlich Pharma (Inst); Genmab (Inst); HiberCell (Inst); Lilly (Inst); Merck (Inst); Natera (Inst); Parker Institute for Cancer Immunotherapy (Inst); PsiOxus Therapeutics (Inst); Revolution Medicines (Inst)
Patents, Royalties, Other Intellectual Property - 23-10471: Methods Of Treating Cancer Using Soluble ?-Glucans and Cd40 Agonistic Monoclonal Antibodies
Travel, Accommodations, Expenses - AstraZeneca/MedImmune
 
William Chapin
Consulting or Advisory Role - Replimune
Research Funding - Boehringer Ingelheim (Inst); Genentech (Inst); Replimune (Inst)
Travel, Accommodations, Expenses - Colorectal Cancer Alliance; DAVA Oncology